{"entity":{"id":"nct06745323","kind":"trial","name":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","aka":["DeLLphi-309"],"tldr":"A phase 2 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.","summary":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC is a phase 2 interventional study registered as NCT06745323 by Amgen, with 252 participants enrolled, started 2025-02-26 and due to reach its primary completion in 2029-05-10. Interventions recorded: Tarlatamab. Conditions listed: Small Cell Lung Cancer (SCLC). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06745323","url":"https://clinicaltrials.gov/study/NCT06745323"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["t-cell-engager"],"targets":[],"drugs":["tarlatamab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06745323","phase":"2","setting":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)","sponsor":"Amgen","started":"2025-02-26","startedType":"actual","enrolled":252,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06745323/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}